產品資訊 - Vaccinate Meningococcal Polysaccharide Vaccine->aspalthic products

登入

加入會員

求助

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Vaccinate Meningococcal Polysaccharide Vaccine

產品分類 :

化學->化學用品->aspalthic products

Vaccinate Meningococcal Polysaccharide Vaccine

產品規格

Model No:	0.5 ml/Vial

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

產品描述

1.Group ACYW135                              
2.Group A+C                                       
3.prevent epidemic cerebrospinal meningitis                                                   


4.purified capsular polysaccharide antigens 



The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135.


 [Description] 
The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution. 
Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides. 
Subsidiary materials: All the components of subsidiary materials approved shall be listed. 
Vaccine diluent: Sterile, pyrogen-free PBS.


[Vaccination Subjects]   At present, the vaccine is only recommended to be used in high-risk population (children and adults) over 2 years of age in the following conditions: 
(1) Travelers or inhabitants of high-risk regions of the serogroup A, C, Y and W135 Neisseria meningitis epidemic areas like Sub-Saharan Africa. 
(2) Persons who do laboratory or vaccine production work and might come in contact with the serogroupA, C, Y and W135 Neisseria meningitis in the air. 
(3) High-risk population in the serogroups Y and W135 Neisseria meningitis epidemic areas estimated by the national Ministry of Health and CDC according to the epidemiological survey. 
[Specifications] 
0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing  200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135). 
[Feature] 
Fill a gap in our country for the first time by developing 4-valent vaccine . 
Improve traditional purification technology to eliminate nucleic acid and protein. 
Improve WHO specifications and high harvest rate. Develop new type of stabilizer. Improve national quality standards. 
 



 <img src="http://i.bosscdn.com/product/18/f2/13/d46381b9bd8edf65b150508726.png@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="-ACYW135" alt="-ACYW135" /> 
 



 
ccls-vaccine.com

其他類似產品